Ramiro Ribeiro Sells 42,544 Shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ EYPT opened at $17.08 on Friday. The firm has a market capitalization of $1.41 billion, a PE ratio of -5.71 and a beta of 1.63. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $19.11. The stock’s 50-day simple moving average is $15.35 and its 200-day simple moving average is $12.92.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%.The firm had revenue of $0.97 million for the quarter, compared to analyst estimates of $3.33 million. On average, sell-side analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP bought a new stake in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $28,556,000. Orbimed Advisors LLC acquired a new position in Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $25,575,000. Aberdeen Group plc lifted its position in shares of Eyepoint Pharmaceuticals by 346.9% in the second quarter. Aberdeen Group plc now owns 1,031,201 shares of the company’s stock worth $9,704,000 after purchasing an additional 800,456 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in Eyepoint Pharmaceuticals during the third quarter valued at $10,767,000. Finally, Rosalind Advisors Inc. acquired a new position in shares of Eyepoint Pharmaceuticals during the 3rd quarter worth $9,256,000. 99.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on EYPT shares. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a research note on Monday, October 20th. Royal Bank Of Canada upped their price objective on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, November 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $29.25.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.